In breast cancer, the inhibitory effect of bisphosphonates on the AKT signaling was examined, whereas in lung cancer the influence of an EGFR inhibition on AKT was tested, and in prostate cancer the activation of AKT after inhibition of the pro-osteoblastic ET-1 receptor was the predominant subject of research papers. The gene discussed is EGFR; the disease is lung carcinoma.